Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Matrix begins two U.S. cancer trials

MATX began a 15-patient, dose-escalating Phase

Read the full 60 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE